🎓 L’Institut Paoli-Calmettes au congrès ESMO 2025
Le congrès annuel de la European Society for Medical Oncology (ESMO), rendez-vous international incontournable en oncologie, se tiendra du 17 au 21 octobre à Berlin. Cet événement réunit chaque année des milliers de spécialistes du monde entier autour des dernières avancées en cancérologie, des innovations thérapeutiques et des grandes tendances de la recherche clinique et translationnelle.
🎯 L’Institut Paoli-Calmettes sera une nouvelle fois fortement représenté, avec la participation de nombreux experts de l’IPC et la présentation de plusieurs travaux de recherche, posters et communications orales, témoignant de la richesse et du dynamisme scientifique de nos équipes.
Un grand bravo à l’ensemble des professionnels impliqués pour cette reconnaissance au sein d’un congrès de référence mondiale !
👉 Retrouvez les présentations et équipes participantes ci-dessous.
Dr Arthur Geraud Crémieux
Un poster TiP de l’essai MATRIX lundi midi session metastatic breast cancer
- Abstract #3065; Poster 618Tip Phase I/II study of tuvusertib, an ATR inhibitor in combinaison with fulvestrant in hormone receptor-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitors plus aromatase inhibitor-based endocrine treatments and in various molecular contexts (MATRIx)
Pr Anthony Gonçalves
Co-auteur
- Poster avec plusieurs co-auteurs IPC – étude de phase précoce promue par l’IPC et soutenue par AAP CLIP2 INCA (TiP t= trials in progress)
- Avec le Pr Rochigneux (Poster) : 1922P CDKN2A mutations negatively impact chemo-immunotherapy efficacy in first-line metastatic non-small cell lung cancers.
- 587P Recent nationwide overall survival trends across subtypes in 33,044 patients with metastatic breast cancer in the French ESME cohort 0:20h
- 515P Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort
- avec le Dr Astier (poster) 328P Adjuvant Olaparib for patients with germline BRCA1 or BRCA2 mutations and high-risk HER2-negative early breast cancer: real world evidence from a French early access program
- oral session :Reliability of Cerebrospinal Fluid (CSF) ctDNA as a Surrogate for Tumor Mutational Profiling in Central Nervous System (CNS) Metastases: Results from the BrainStorm (OncoDistinct006)
- 618TiP Phase I/II study of tuvusertib, an ATR inhibitor in combinaison with fulvestrant in hormone receptor-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitors plus aromatase inhibitor-based endocrine treatments and in various molecular contexts (MATRIx)
Dr Renaud Sabatier
Deux posters en lien avec un essai auquel il a participé et dont le résultat principal a été publié en Mai dans Annals of Oncology
- 1102P Contribution of bevacizumab use to safety outcomes in FIRST/ENGOT-OV44, presenter Andrès Redondo (GEICO, Madrid, Spain)
- 1101P FIRST/ENGOT-OV44 trial: does the addition of dostarlimab impact niraparib tolerability, exposure, or dose modifications?, presenter Kahleen Moore (University of Oklahoma, USA)
Dr Philippe Rochigneux
Un travail en collaboration entre les oncologues thorax et la biologie moléculaire de l’IPC (messieurs Cornel Popovici et Alexandre Astier)
- NSCLC, metastatic
- 1922P – CDKN2A mutations negatively impact chemo-immunotherapy efficacy in first-line metastatic non-small cell lung cancers.
Presentation Number :1922P Speakers
Dr Cécile VICIER
2 posters :
- 1029eTiP – A Phase 1/2 Open-label Study of NDI-219216, a WRN Inhibitor, in Patients with Advanced Solid Tumors With or Without Microsatellite Instability /Deficient Mismatch Repair
- 1738eTiP – IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the IMMUNOtherapy (Domvanalimab + Zimberelimab) in patients with advanced RARE cancers: THE NEUROENDOCRINE TUMORS COHORT.
Dr Gwenaelle Gravis
Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment Speakers Marit Ahrens (Frankfurt am Main, Germany)
Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer Speakers Lothar Bergmann (Frankfurt am Main, Germany)
Dr Alexandre Tassin de Nonneville
Trois posters :
- Abstract 2519 – HEROES: De-escalation of anti-HER2 therapies in HER2-positive metastatic breast cancer with long-term persistent response and undetectable minimal residual disease in circulating tumor DNA
- 617TiP – Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+/HER2– advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy
- Abstract 2274 -Adjuvant Olaparib for patients with germline BRCA1 or BRCA2 mutations and high-risk HER2-negative early breast cancer: real world evidence from a French early access program
Dr Mathilde Guérin
- Title : End-of-Life Care Intensity and Palliative Care Access in Adolescents and Young Adults with Cancer : A Retrospective Single-Center Study / Autors : Vanessa Collin1, Mathilde Guerin2, Camille Rouzaud3, Marie-Anne Hospital3 Faézeh Legrand3, Géraldine Capodano1, Fanny Dupeyre-Alvarez1, Nathalie Ramirez1, Marion Bruge-Ansel1, Julien Lorandi1, Maïalen Lauzin1, Laura Le Polles1, Marie Domon1, Jean-Louis Kurmann1, Caroline Maindet1, Aurélien Proux1
Dr Christelle De La Fouchardiere
- Squamous anal cancer: A rare HPV-driven tumour where early diagnosis is key